Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 131 of 5804
-
Double-Drug attack targets tough lung cancer
Disease control Recruiting nowThis is a single-arm, exploratory phase Ib/II study with a seamless design to evaluate the safety and efficacy of Vebreltinib combined with furmonertinib as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sens…
Phase: PHASE1, PHASE2 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Zapping the brain without surgery: a new hope for Parkinson's?
Disease control ENROLLING_BY_INVITATIONThis study aims to explore the therapeutic effects of noninvasive deep brain electrical stimulation using temporal interference principles (Temporal Interference Stimulation, TIS) on both motor and non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonia…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New weekly shot could help chinese adults shed pounds and control diabetes
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet an…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
Disease control Not yet recruitingThis study tests whether a combination of three treatments - dexamethasone (a steroid), intravenous immunoglobulin (IVIG, a protein that helps the immune system), and an extra dose of donor mononuclear cells - can safely lower harmful antibodies called donor-specific antibodies (…
Phase: PHASE2 • Sponsor: Hematology department of the 920th hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New pastille could change head and neck cancer treatment
Disease control Not yet recruitingThis Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 admini…
Phase: PHASE3 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple attack on liver cancer: blocking blood flow plus immune boost shows promise
Disease control Recruiting nowThe safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Drug duo takes on rare head and neck tumors
Disease control Recruiting nowThis is a prospective, multicenter, multi-cohort, Phase II clinical trial enrolling patients with unresectable, recurrent, or metastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or salivary gland malignancies (excluding adenoid cystic carcinoma) who have…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to boost chemo for rare blood cancer
Disease control Not yet recruitingThe goal of this clinical study is to find the best way to combine the study drug BEBT-908 (ifupinostat hydrochloride for injection) with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for treating previously untreated peripheral T-cell lymphoma, and to find ou…
Phase: PHASE2 • Sponsor: BeBetter Med Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New screening strategy aims to catch colorectal cancer early in younger veterans
Prevention Not yet recruitingColorectal cancer is a leading cause of cancer death among Veterans. The starting age for colorectal cancer screening has been lowered from 50 to 45 years in response to the rising incidence of early-onset colorectal cancer (EOCRC), but how to best engage younger Veterans in scre…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
New antibody therapy aims to stop chronic kidney transplant rejection
Disease control Not yet recruitingThis clinical trial aims to determine whether a bispecific T-cell engager (BiTE) targeting BCMA×CD3 effectively treats chronic active antibody-mediated rejection (cAMR) in kidney transplant recipients. The study also investigates the safety of BiTE in this patient population. Th…
Phase: PHASE4 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New blood tests aim to catch ovarian cancer earlier
Diagnosis Not yet recruitingOvarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes. Recent research has focused on the development of blood-based tests, sometimes referred to as …
Sponsor: National and Kapodistrian University of Athens • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
Less may be more: smaller lung surgery tested against standard for early cancer
Disease control Not yet recruitingSOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung cancer (NSCLC) measuring \<=2 cm. Eligible participan…
Phase: NA • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Exercise-Triggered heart valve leak targeted in new trial
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether mitral valve transcatheter edge-to-edge repair (TEER) in addition to guideline-directed medical therapy (GDMT) can improve clinical outcomes and symptoms in heart failure patients with non-severe secondary mitral regurgitation (…
Phase: NA • Sponsor: Jena University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
Disease control OngoingThis multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC). Participants will receive two cycles of induction chemoimmunotherapy with sugemalimab, nab-paclitaxel, a…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a gentler steroid dose protect children's kidneys without the harsh side effects?
Disease control Recruiting nowChildhood-onset systemic lupus erythematosus (cSLE) is a severe chronic autoimmune disease with a high burden of major-organ involvement. Lupus nephritis (LN) affects more than half of children with SLE, and proliferative LN-including class III, IV, III+V, and IV+V disease-is ass…
Phase: PHASE4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Blood test could guide cancer treatment, reducing side effects
Disease control Not yet recruitingThe purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival outcomes in participants with stage I, II, or III, HPV-a…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Blood test may take the guesswork out of transplant drug dosing
Disease control Not yet recruitingIMPAKT is a research study that looks at whether a blood test called Prospera™ can help doctors better adjust anti-rejection medications, compared to the usual way doctors manage these medications without using this test.
Phase: NA • Sponsor: Natera, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New Three-Drug cocktail aims to beat aggressive leukemia
Disease control Not yet recruitingThis study is testing a new treatment combination called RAVEN, which includes revumenib, azacitidine, and venetoclax, in patients who are newly diagnosed with a specific type of acute myeloid leukemia (AML) called KMT2A- translocated AML. People with this type of AML often have…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
AI could spot hidden cancers on routine CT scans
Diagnosis Not yet recruitingThis study aims to develop and validate a deep learning-based opportunistic multi-cancer screening system using routine non-contrast chest-abdomen-pelvis CT examinations, including CHANCE-Breast, CHANCE-Liver, CHANCE-Kidney, and CHANCE-Bladder, for the early detection of breast, …
Sponsor: Lian Yang • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New daily pill could help manage weight for years
Disease control Not yet recruitingStudy GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination …
Phase: PHASE3 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC